BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...
BioCentury | Dec 18, 2020
Product Development

Sangamo’s Macrae on where the gene editing field is headed: a BioCentury audio interview

Gene-editing assets may be the next additions to big pharma shopping lists as gene therapies are now becoming core modalities alongside small molecules and mAbs, according to Sandy Macrae, who anticipates...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one...
BioCentury | Dec 18, 2020
Deals

Merck & Co. builds presence in bispecifics with Janux deal

Merck & Co. continues to build out its immuno-oncology pipeline beyond Keytruda, this time via a deal with David Campbell’s California start-up Janux that increases the pharma’s presence in the...
BioCentury | Dec 15, 2020
Product Development

Vaccines march forward & CAR Ts move earlier: a BioCentury podcast

On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the latest advances and setbacks among COVID-19 vaccines in the wake of FDA’s emergency use authorization on Friday for Pfizer and BioNTech’s...
BioCentury | Dec 11, 2020
Product Development

CAR Ts make the move to earlier lines of treatment despite access barriers

CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment....
BioCentury | Dec 8, 2020
Product Development

Dec. 7 ASH Quick Takes: CRISPR, Vertex update durability for edited cell therapy; plus J&J- Legend, Kura, Fate, Pfizer, Autolus and Affimed

Vertex, CRISPR update long-term data for edited cell therapyCRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) showed seven transfusion-dependent β thalassemia patients in the CLIMB-Thal-111 study remain transfusion-free for up to 18 months following CTX001...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...
Items per page:
1 - 10 of 314